EGM
MRSN

Engineers Gate Manager’s Mersana Therapeutics MRSN Stock Holding History

Engineers Gate Manager’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-683
Closed -$24.4K – 2429
2024
Q4 		$24.4K Buy
+683
New +$35.3K ﹤0.01% 2148
2024
Q1 		– Sell
-1,748
Closed -$101K – 2162
2023
Q4 		$101K Buy
1,748
+744
+74% +$29.9K ﹤0.01% 1773
2023
Q3 		$31.9K Sell
1,004
-626
-38% -$29.8K ﹤0.01% 1686
2023
Q2 		$134K Sell
1,630
-1,136
-41% -$166K 0.01% 1534
2023
Q1 		$284K Buy
2,766
+526
+23% +$73.8K 0.01% 1271
2022
Q4 		$328K Sell
2,240
-100
-4% -$16.9K 0.02% 1145
2022
Q3 		$395K Buy
+2,340
New +$380K 0.02% 954
2022
Q2 		– Sell
-405
Closed -$40K – 2121
2022
Q1 		$40K Sell
405
-415
-51% -$48.5K ﹤0.01% 1762
2021
Q4 		$128K Buy
+820
New +$160K 0.01% 1773
2021
Q3 		– Sell
-1,744
Closed -$592K – 1845
2021
Q2 		$592K Buy
1,744
+1,270
+268% +$481K 0.04% 737
2021
Q1 		$192K Buy
+474
New +$230K 0.01% 1611

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Engineers Gate Manager's MRSN Position: Q1 2025 in Review

Engineers Gate Manager sold out of Mersana Therapeutics (MRSN) in Q1 2025, closing a stake of 683 shares — an estimated $24.4K sold.

Engineers Gate Manager first reported a position in MRSN in Q1 2021 and held it in 11 quarters. The position peaked at $592K in Q2 2021. 108 funds tracked by Wall St. Rank hold MRSN as of Q1 2025.

  • Engineers Gate Manager reported no remaining Mersana Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Engineers Gate Manager sold 683 Mersana Therapeutics shares in Q1 2025, an estimated $24.4K.
  • Engineers Gate Manager first reported a position in Mersana Therapeutics in Q1 2021 and held it in 11 quarters.
  • Engineers Gate Manager's Mersana Therapeutics position peaked at $592K in Q2 2021.
  • 108 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2025.

Based on Engineers Gate Manager's 13F filing for Q1 2025, filed 15 May 2025.